KATHERINE Results Back New Adjuvant Standard for HER2+ Breast Cancer

Dr. Charles Geyer discusses the phase III KATHERINE trial, which compared ado-trastuzumab emtansine vs trastuzumab in HER2-positive early breast cancer.

Source: CancerNetwork - December 12, 2018 Category: Cancer & Oncology Authors: Charles E. Geyer Jr, MD Source Type: news